NL-OMON38274已完成2 期
Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas - mesalazine effects in sporadic colorectal adenoma patients
niversitair Medisch Centrum Utrecht0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Within 6 months before study entry having undergone complete colonoscopy with polypectomy for removal of sporadic adenomatous polyps. This should be 2 or more adenomas, irrespective of size, and/or one adenoma with a diameter of at least 1 cm and/or with proximal localization and/or with villous aspects or high-grade dysplasia.
- •- age 50-75 years
排除标准
- •- inflammatory bowel disease
- •- familial colorectal cancer syndrome
- •- history of colorectal carcinoma
- •- history of surgery to the large bowel (except appendectomy)
- •- chronic renal insufficiency
- •- chronic hepatic insufficiency
- •- allergy to salicylates
- •- diabetes mellitus
- •- coagulation disorder or anticoagulant use, which cannot be temporarily discontinued
- •- regular intake of thiopurines, methotrexate or cyclosporin
- •- prescription use of aspirin (high- and low-dose) or other NSAIDs
研究者
相似试验
进行中（未招募）
不适用
Mesalazine for the prevention of colorectal cancer: effects in patients with a history of sporadic adenomatous polypsEUCTR2011-001815-29-NLMC Utrecht
已完成
2 期
Mesalazine Effects in Sporadic Colorectal Adenoma PatientsSporadic Colorectal AdenomaNCT01894685UMC Utrecht74
进行中（未招募）
不适用
Efficacy of mesalazine in the long term prevention of diverticulitis relapses.Randomised study, double blind, controlled vs placebo.EUCTR2005-001459-39-ITSOFAR SPA
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136